Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-β-hydroxylase)

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9744223
SERIAL NO

14073210

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PANACEA PHARMACEUTICALS209 PERRY PARKWAY SUITE 13 GAITHERSBURG MD 20877

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Biswas, Biswajit Germantown, US 15 51
Ghanbari, Hossein A Potomac, US 46 297
Merril, Carl R Bethesda, US 41 579

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 28, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 28, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00